Pharmaceuticals

Monoclonal antibodies: magic bullets with a hefty price tag

BMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e8346 (Published 12 December 2012)
Cite this as: BMJ 2012;345:e8346

Recent rapid responses

Rapid responses are electronic letters to the editor. They enable our users to debate issues raised in articles published on bmj.com. Although a selection of rapid responses will be included as edited readers' letters in the weekly print issue of the BMJ, their first appearance online means that they are published articles. If you need the url (web address) of an individual response, perhaps for citation purposes, simply click on the response headline and copy the url from the browser window.

Displaying 1-1 out of 1 published

The price of monoclonal antibodies bears little relationship to the development and production costs.(1). Denosumab, a highly specific monoclonal antibody, which incidentally is advertised on the back cover of this issue of BMJ, costs the NHS only £310 pounds per dose.

The pricing of a near monopoly product is always related to 'how much the market can bear'. Markets tend be ‘inefficient’ with monopoly products and suppliers.
In 1914, faced with rising drug prices, the BMA Pharmaceutical Committee, recommended that ‘Government should exercise its powers’ to control price inflation. Perhaps that advice still remains relevant today.(2)

1. Shaughnessy AF. Monoclonal antibodies: magic bullets with a hefty price tag. BMJ. 2012 Dec 12;345(dec12 1):e8346–e8346.

2. Price of Drugs. Supplement 542. BMJ. 1914 Sep 12;2(2802):S169–S172.

Competing interests: Honararia from various pharmaceutical companies including Amgen, Sanofi and Roche.

Santhanam Sundar, Consultant Oncologist

Nottingham University Hospital NHS Trust, Nottingham. NG5 1PB

Click to like:

THIS WEEK'S POLL